Monitoring mast cell activation by prostaglandin D2 in vivo

Thorax

Volumn 59, Issue 6, 2004, Pages 453-455

  Dahlen S E ^a   Kumlin, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLERGEN; CELL MARKER; CYTOKINE; GROWTH FACTOR; HEPARIN; HISTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN D2; TRYPTASE; BIOLOGICAL MARKER;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; CELL ACTIVATION; CELL FUNCTION; DRUG HYPERSENSITIVITY; EDITORIAL; EFFECTOR CELL; HUMAN; IMMUNOASSAY; IN VIVO STUDY; LUNG DISEASE; MAST CELL; MASTOCYTOSIS; MEASUREMENT; METABOLISM; METABOLITE; MONITORING; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SENSITIVITY ANALYSIS; URINALYSIS; VALIDATION PROCESS; NOTE; PHYSIOLOGY;

BIOLOGICAL MARKERS; HUMANS; MAST CELLS; PROSTAGLANDIN D2;

EID: 2942659877     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.026641     Document Type: Editorial

References (32)

1. Brightling CE, Bradding P, Symon FA, et al. Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002;346:1699-705.
2. Grashoff WF, Sont JK, Sterk PJ, et al. Chronic obstructive pulmonary disease: role of bronchioloar mast cells and macrophages. Am J Pathol 1997;151:1785-90.
3. Taube C, Holtz O, Mucke M, et al. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1810-5.
4. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-6.
5. Inoue Y, King TE Jr, Tinkle SS, et al. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996;149:2037-54.
6. Björck T, Gustafsson L-E, Dahlén S-E. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of histamine and leukotrienes. Am Rev Respir Dis 1992;145:1087-95.
7. Eggleston PA, Kagey-Sobotka A, Schleimer R, et al. Interaction between hyperosmolar and IgE-mediated histamine release from bosophils and mast cells. Am Rev Respir Dis 1984;130:86-91.
8. Marshall JS, McCurdy JD, Olynych T. Toll-like receptor operated activation of mast cells: implications for allergic disease? Int Arch Allergy Immunol 2003;132:87-97.
9. Howarth PH, Pao GJK, Church MK, et al. Exercise- and isocapnic hyperventilation-induced bronchoconstriction in asthma, relevance of circulating basophils to measurements of plasma histamine. J Allergy Clin Immunol 1984;73:391-9.
10. O'Sullivan S, Roquet A, Dahlén B, et al. Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin Exp Allergy 1998;28:1332-9.
11. Schwartz LB, Irani A-MA, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138:2611-5.
12. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001;25:553-62.
13. 2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004;59:459-64.
14. 2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982;129:1627-31.
15. 2 into human airways during acute antigen challenge. N Engl J Med 1986;315:800-4.
16. 2 metabolites as markers of mast cell activation in asthma. Acta Physiol Scand Suppl 1999;644:1-74.
17. 2 in human and rat mast cell lines. J Biol Chem 2003;278:4725-9.
18. 2 in a normal human male volunteer. J Biol Chem 1985;260:13172-80.
19. 2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proc Natl Acad Sci USA 1985;82:6030-4.
20. 2, that inhibits platelet aggregation and constricts blood vessels. J Biol Chem 1985;260:14621-5.
21. 2 is a potent contractile agonist of human and guinea pig airways. J Clin Invest 1987;79:978-83.
22. 2, which contracts human coronary artery rings. Adv Prostaglandin Thromboxane Leukot Res 1987;17A:427-9.
23. 2 in patients with systemic mastocytosis. N Engl J Med 1980;303:1400-4.
24. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421-32.
25. 2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometry. Prostaglandins Other Lipid Mediat 1999;57:149-65.
26. O'Sullivan S, Roquet A, Dahlén B, et al. Evidence for mast cell activation during exercise-induced bronchoconstriction. Eur Respir J 1998;12:345-50.
27. Brannan JD, Gulliksson M, Anderson SD, et al. Evidence of mast cell activation and leukotriene release after mannitol inhalation. Eur Respir J 2003;22:491-6.
28. 2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003;111:743-9.
29. 2 as a mediator of allergic asthma. Science 2000;287:2013-7.
30. Roquet A, Dahlén B, Kumlin M, et al. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997;155:1856-63.
31. Sundström E, Låstbom L, Ryrfeldt Å, et al. Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Ther 2003;307:408-18.
32. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985;313:65-70.